Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6193 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Meghan E Whalen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, University of California-San Francisco, San Francisco General Hospital, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Antimalarials, Artemether, Lumefantrine Drug Combination, Artemisinins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NICHD NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Malaria and HIV co‐infection are prevalent in sub‐Saharan Africa causing significant drug interactions with co‐treatment. We previously reported a 30%‐70% reduction in exposure to the standard 3‐day (6‐dose) artemether‐lumefantrine (AL) treatment for malaria when given with efavirenz‐based HIV therapy, impacting malaria reinfection risk. We conducted a prospective, randomized study comparing the 3‐day regimen to an extended 5‐day (10‐dose) regimen with pharmacokinetic sampling for artemether, dihydroartemisinin, lumefantrine, and desbutyl‐lumefantrine (DBL) over 42 days. The primary outcome was comparative pharmacokinetics between regimens compared among children with HIV and among children without HIV receiving a 3‐day regimen as controls (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]). Children with HIV (n = 57; median age 10.8 years [range 3.4‐17.1]; median weight 26.6 kg [range 14.6‐54.5]) contributed 76 malaria episodes, with 71 included in the analysis. Another 97 children without HIV (median age 5.3 years [range 1.4‐13.9]; median weight 17.3 kg [range 8.7‐39.1]) contributed 114 episodes of malaria, with 109 included in the analysis. In the setting of efavirenz, artemether, dihydroartemisinin, lumefantrine, and DBL cumulative exposure was 2.09, 2.31, 1.90, and 1.65 fold higher with 5‐day versus 3‐day AL (all P < .001), and comparable to 3‐day AL in children without HIV. The extended regimen in children with HIV did not result in a statistically significant reduction in recurrence risk at 28 or 42 days. Extending the duration of AL to 5 days compensated for a clinically significant reduction in all components of AL in the context of EFV‐based antiretroviral therapy in young children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, University of California-San Francisco, San Francisco General Hospital, San Francisco, CA, USA.
- Infectious Disease Research Collaboration, Kampala, Uganda.
- Yale School of Public Health, New Haven, CT, USA.
- Department of Epidemiology and Biostatistics, and Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA.
- Makerere University College of Health Sciences, Kampala, Uganda.
ORCID-Profile: Justin Goodwin
Förderung
- NICHD NIH HHS
Zitieren
APA
Whalen, M. E., Kajubi, R., Goodwin, J., Orukan, F., Colt, M., Huang, L., Richards, K., Hoffmann, T. J., Aweeka, F. T., Parikh, S., & Mwebaza, N. (2025). Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6193
Vancouver
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, et al. Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6193
BibTeX
@article{Whalen2025,
author = {Whalen, Meghan E and Kajubi, Richard and Goodwin, Justin and Orukan, Francis and Colt, McKenzie and Huang, Liusheng and Richards, Kacey and Hoffmann, Thomas J and Aweeka, Francesca T and Parikh, Sunil and Mwebaza, Norah},
title = {Extended Treatment Duration of Artemether‐Lumefantrine in Ugandan Children with HIV on Efavirenz‐Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6193}
}
EUVIMED